Navigation Links
Quincy Bioscience Earns NSF Good Manufacturing Practice (GMP) Registration for Facilities
Date:7/18/2013

Madison, WI (PRWEB) July 18, 2013

Quincy Bioscience announced today that its Pinehurst manufacturing facility is now a Good Manufacturing Practices (GMP) facility registered by NSF International.

Earning GMP registration from NSF International verifies that Quincy Bioscience’s facility has the proper methods, equipment, facilities, and controls in place for producing dietary supplement products. The NSF GMP’s were developed in accordance with the U.S. Food and Drug Administration’s (FDA) 21 CFR part 111 regulation on dietary supplement manufacturing, packaging, and distribution. Utilizing GMP guidelines assists companies in developing and maintaining proper controls in their manufacturing process so that products are processed, manufactured and labeled in a consistent manner, and meet quality standards.

"Earning NSF GMP registration for their Pinehurst manufacturing facility provides Quincy Bioscience with a system for continual improvement, as well as demonstrates to customers and supply chain partners their commitment to quality and safety," said Ed Wyszumiala, General Manager of NSF International’s Dietary Supplement programs.

"We’re proud to achieve this recognition of our manufacturing facilities," says Mark Underwood, President of Quincy Bioscience. "We take good manufacturing practices very seriously, and we look forward to continuing our practice of excellence."

Quincy Bioscience manufactures Prevagen, the #1 selling brain health supplement in chain drug pharmacies. Prevagen contains the main ingredient 'apoaequorin', a protein originally discovered in a jellyfish which is used to improve mild memory loss associated with aging.

For more information about Quincy Bioscience, please visit the website.

Read the full story at http://www.prweb.com/releases/PrevagenManufacturer/NSFQualityProduction/prweb10937619.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Flagship Biosciences Introduces a New Technique for Measuring Fibrosis in Nonalcoholic Steatohepatitis
2. Pressure BioSciences, Inc. Closes Final Tranche of Series J Above Market Private Placement - Total Amount Raised in PIPE Slightly Exceeds $2 Million Goal
3. Eagle Biosciences Introduces Highly Sensitive Calprotectin ELISA Assay Kit
4. IntelliCell BioSciences Receives US Patent for its Stem Cell Extraction Technology
5. MEI Pharma Adds Former YM BioSciences CEO Nick Glover To Board Of Directors
6. PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756
7. Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update
8. Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego
9. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
10. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
11. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... The new and improved Oakton® pocket testers, ... even stand upright with a new cap design that is versatile, functional and leakproof. ... who need to test water quality. , The Oakton pocket testers have many user-friendly ...
(Date:9/19/2017)... ... September 19, 2017 , ... The ... cybersecurity regulations have transitioned into full force and effect. The law requires ... (“Covered Entities”) to conduct an annual, professional, comprehensive cybersecurity risk assessment, with ...
(Date:9/18/2017)... ... September 18, 2017 , ... ... business process optimization firm for the life sciences and healthcare industries, announces ... 2017 conference. , What: Digital Transformation in Medical Device – The Journey to ...
(Date:9/14/2017)... ... September 14, 2017 , ... ... launch of its CliniControl™ (CC) product portfolio, clinically-relevant starting and ancillary materials ... of human Mesenchymal Stem/Stromal Cell (hMSC)-based therapies. The CliniControl product portfolio will ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
Breaking Biology News(10 mins):